🇭🇰 港交所INSILICODoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 08:15:00时区推断·⟳ 抓取 08:15:39·⚡ 决策 10-20 08:17:39 +2m00s·7.6 天前
英矽智能达成与施维雅AI药物研发合作的首个早期发现里程碑，触发金额未披露的里程碑付款
正向但极弱的软催化：早期发现阶段、付款金额未披露、单一里程碑相对229亿港元市值不具重大性；叠加标的近20日累计下跌27%、近60日高回撤40%的强下行趋势，同公司前期同类靶点提名公告均伴随大跌，正期望不足。
📄 原文INSILICO↗ 原文
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 英矽智能（03696.HK）
软催化、低materiality：早期发现里程碑付款金额未披露(通常仅数百万美元一次性)，相对229亿港元市值无实质增量，8.88亿美元为多年理论上限且3200万美元首付早已公布；同时股价20日跌27%、同类研发公告日(10/13)仍跌7.8%，强下行趋势中追多正期望不足；事件非利空亦不满足做空红线。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
英矽智能达成与Servier合作的首个早期发现里程碑，平台验证意义正面，但付款金额未披露、处临床前阶段，对229亿港元市值无实质增量；且股价处于强劲下行通道(20日-27%)，软催化难以扭转趋势，风险收益不支持做多，亦无做空利空，回避。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 low ↗
消息传播链
- 英矽智能自愿公告达成与Servier合作的首个早期发现里程碑，触发金额未披露付款；公告落款香港2026年10月20日。
关键理由
- 合作进展验证Pharma.AI平台执行力，但早期发现里程碑通常仅为数百万美元级一次性付款，且本次金额未披露，相对229亿港元市值无实质弹性
- 总价值8.88亿美元为多年、多里程碑、含成功条件的理论上限，3200万美元首付款已于2026年初公布，本公告不含新增财务指引或大额合同
主要风险
- 标的近20日跌27%、10月7-15日多次单日跌8-10%，即便出现同类靶点提名利好(10月13日VAV1)当日仍跌7.8%，显示系统性抛压，软催化可能继续高开低走
- 公司PE为负(尚未盈利)，股价对题材情绪与现金消耗高度敏感，事件证伪或大盘风险偏好走弱时波动剧烈(20日波动率6.3%/日)
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
10月7-15日多个交易日单日跌8-10%，同类研发利好公告日仍大跌，存在持续抛压；未发现能立即反转趋势的新增重大利好
检索:InSilico Medicine 3696.HK October 2026 下跌 利空 配售 套现 现金 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-07-09 · 影响 invalidates
公司曾于2026年7月发布正面盈利预告，且本次为合作正向进展，不构成做空催化
检索:InSilico Medicine Servier milestone positive profit warning 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:自身近期类比强化回避结论：不据此消息追多；因非利空亦不开空
方向:无可供event_study校准的同主体/同机制首发先例面板
涨幅量级:不足：未构建外部先例；但本标的自身近期可比节点提供了更直接的背景——10月13日同类靶点提名(VAV1分子胶)公告当日股价仍跌7.82%，10月8日跌7.7%，显示此类早期研发进展公告在当前下行趋势中未带来正收益
形态:本公司近两周的实际盘面反复呈现'利好公告日仍大跌'，提示软催化在抛压期失效、高开低走风险高
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`insilico medicine 3696 early drug discovery milestone servier | insilico medicine servier milestone payment ai drug discovery | 英矽智能 施维雅 里程碑付款 888 million`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 1,349 ms
{ - web_search 成功 doubao_search · 1,079 ms
豆包搜索结果（原始查询:InSilico Medicine 3696.HK stock drop October 2026 英矽智能 下跌；API SearchType:web）
原文全文
展开原文 · 3,142 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.
INSILICO MEDICINE
InSilico Medicine Cayman TopCo
英矽智能
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3696)
VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE TRIGGERS A MILESTONE PAYMENT
IN AI-DRIVEN R&D COLLABORATION WITH SERVIER FOR
ACHIEVING EARLY DRUG DISCOVERY MILESTONE
This announcement is made by InSilico Medicine Cayman TopCo (the “ Company ”, together
with its subsidiaries, the “Group” or “Insilico Medicine”) on a voluntary basis to inform the
shareholders and potential investors of the Company about the latest business updates of the
Group.
The board of directors of the Company (the “Board”) is pleased to announce that the Company
has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery
collaboration with Servier, an independent international pharmaceutical group governed by a
foundation.
First announced in early 2026, the multi-year research and development (R&D) collaboration
carries a total value of up to USD888 million with USD32 million in upfront and near-term R&D
milestone payments. Under the collaboration, the two companies initiated two distinct R&D
programs for oncology leveraging Insilico Medicine’s proprietary end-to-end AI platform, Pharma.
AI. Both programs have completed target nominations.
Following the successful fulfillment of predefined program criteria, Insilico Medicine has reached
the early drug discovery milestone for the first program. Achieving this milestone triggers a
milestone payment in an undisclosed amount from Servier to Insilico Medicine.
1
Forward Looking Statement
There is no assurance that any forward-looking statements regarding the business development of
the Group in this announcement or any of the matters set out herein are attainable, will actually
occur or will be realized or are complete or accurate. The financial and other data relating to the
Group as disclosed in this announcement has also not been audited or reviewed by its auditors.
Shareholders and/or potential investors of the Company are advised to exercise caution when
dealing in the shares of the Company and not to place any excessive reliance on the information
disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice
from professional advisors.
By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO
Hong Kong, October 20, 2026
As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D.
and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive
director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman
Kyrychynskyi as independent non-executive directors.
2
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.
INSILICO MEDICINE
InSilico Medicine Cayman TopCo
英矽智能
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3696)
VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE TRIGGERS A MILESTONE PAYMENT
IN AI-DRIVEN R&D COLLABORATION WITH SERVIER FOR
ACHIEVING EARLY DRUG DISCOVERY MILESTONE
This announcement is made by InSilico Medicine Cayman TopCo (the “ Company ”, together
with its subsidiaries, the “Group” or “Insilico Medicine”) on a voluntary basis to inform the
shareholders and potential investors of the Company about the latest business updates of the
Group.
The board of directors of the Company (the “Board”) is pleased to announce that the Company
has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery
collaboration with Servier, an independent international pharmaceutical group governed by a
foundation.
First announced in early 2026, the multi-year research and development (R&D) collaboration
carries a total value of up to USD888 million with USD32 million in upfront and near-term R&D
milestone payments. Under the collaboration, the two companies initiated two distinct R&D
programs for oncology leveraging Insilico Medicine’s proprietary end-to-end AI platform, Pharma.
AI. Both programs have completed target nominations.
Following the successful fulfillment of predefined program criteria, Insilico Medicine has reached
the early drug discovery milestone for the first program. Achieving this milestone triggers a
milestone payment in an undisclosed amount from Servier to Insilico Medicine.
1
Forward Looking Statement
There is no assurance that any forward-looking statements regarding the business development of
the Group in this announcement or any of the matters set out herein are attainable, will actually
occur or will be realized or are complete or accurate. The financial and other data relating to the
Group as disclosed in this announcement has also not been audited or reviewed by its auditors.
Shareholders and/or potential investors of the Company are advised to exercise caution when
dealing in the shares of the Company and not to place any excessive reliance on the information
disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice
from professional advisors.
By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO
Hong Kong, October 20, 2026
As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D.
and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive
director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman
Kyrychynskyi as independent non-executive directors.
2
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
7588a037a8· 2026-10-20 08:17 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前